- Organizations: 4D Molecular Technologies
Pipeline
4DMT releases 60-week phase 2 analysis on wet AMD gene therapy
Reported at ASRS, data supports sustained vision gains and a 78% reduction in supplemental injections for 4D-150’s highest dose as company preps for phase 3 trial.
Business
4DMT cuts 25% of workforce and fast-tracks wet AMD gene therapy program
Company reports streamlined planning to advance phase 3 clinical trials of 4D-150, under evaluation to deliver a single, low-dose, and sustained multi-year intravitreal injection.
Pipeline
FDA grants RMAT designation to 4DMT for DME gene therapy
4D-150 provides a multi-year sustained delivery of anti-VEGF from the retina via a single, low-dose IVT delivery—potentially reducing the need for frequent bolus injections.Pipeline
Positive 52-week data supports 4DMT's wet AMD gene therapy
PRISM trial extension cohort finds 4D-150 continues to be well tolerated after 3 years of follow-up; phase 3 program initiation to begin this year.
Pipeline
FDA clears 4DMT's IND for genetic GA treatment
Novel genetic medicine is formulated as a proprietary low-dose intravitreal AAV vector with plans for phase 1 clinical trial initiation expected in H2 2024.
Pipeline
4DMT releases positive interim data on phase 2 AMD gene therapy trial
Clinical results from the PRISM trial support a single, low-dose intravitreal delivery.
Business
Astellas and 4DMT enter into licensing deal
Agreement gives Astellas access to 4DMT’s proprietary, intravitreal 4100 vector for rare ophthalmic disease targets.
Pipeline